[Retracted] Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway

Figure 2

Hsa-miR-128a influenced the inhibition rate of pembrolizumab on laryngeal cancer cells. (a) The immunotherapy assay was performed on laryngeal cancer Hep2 cells. (i) 3 μg, 6 μg, or 12 μg pembrolizumab was added to Hep2 cells and cultured for 24 hours. The inhibition rate was significantly different among wild-type Hep2 cells, Hep2 cells overexpressing hsa-miR-128a, and negative control RFP cells (). (ii) Hep2 cells treated with pembrolizumab were cultured for 48 hours. The inhibition rate differed significantly among the three groups (). (b) The immunotherapy assay was performed in AMC-HN8 laryngeal cancer cells. (i) Wild-type AMC-HN8 cells, AMC-HN8 cells overexpressing hsa-miR-128a, and negative control RFP cells were treated using either 3 μg, 6 μg, or 12 μg of pembrolizumab and incubated for 24 hours. The group with higher expression levels of hsa-miR-128a had markedly higher inhibition rate than those in the other two groups (). (ii) The three groups of cells were incubated with pembrolizumab for 48 hours, and the inhibition rates of AMC-HN8 cell group overexpressing hsa-miR-128a were significantly higher than those in the other two groups ().

(a)

(b)